Podcasts about reachmd

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Laney K. Jones, PharmD, MPH Patients with familial hypercholesterolemia (FH) are at an increased risk of developing coronary heart disease at a young age. So what's on the horizon for using implementation science strategies in treating patients with FH? Learn more about implementation science as Dr. Mary Katherine Cheeley discusses this with Dr. Laney Jones, Associate Professor at Geisinger's Department of Genomic Health.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Paul Kwo, MD Between 2.4 and 4.7 million people have hepatitis C in the United States, but not all have access to proper treatments. So how can clinicians reach more people in the community with this virus? Dr. Peter Buch will give us further insight with Dr. Paul Kwo, Professor of Medicine and the Director of Hepatology at Stanford University.

Host: Marc E. Agronin, MD Guest: Richard S. Isaacson, MD TBD

Host: Marc E. Agronin, MD Guest: Richard S. Isaacson, MD TBD

CME credits: 1.00 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/importance-benefits-of-early-diagnosis/14649/ TBD

CME credits: 1.00 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/standard-of-care/14652/ TBD

CME credits: 1.00 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/pathology-amyloid-vs-tau/14653/ TBD

CME credits: 1.00 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/what-is-immunotherapy/14654/ TBD

Host: Sara W. Koblitz Guest: Michael J. Thorpy, MD While most clinicians are aware of a drug being either “approved” or “not approved” by the FDA, many are not familiar with the term “tentative approval.” Leading experts, attorney Sara Koblitz, JD, and Dr. Michael Thorpy, review the FDA approval process, explore how “tentative approval” is currently impacting treatment in the field of sleep medicine, and discuss how “non-drug” issues are related to delayed FDA approval. Review the latest safety and efficacy pivotal trial data associated with once-nightly sodium oxybate and find out if we're truly on the cusp of a new awakening in sleep medicine.

Guest: Marc E. Agronin, MD TBD

CME credits: 1.00 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/differences-among-agents/14655/ TBD

Host: Marc E. Agronin, MD Guest: Richard S. Isaacson, MD TBD

Host: Marc E. Agronin, MD Guest: Richard S. Isaacson, MD TBD

Host: Marc E. Agronin, MD Guest: Richard S. Isaacson, MD TBD

Guest: Marc E. Agronin, MD TBD

Host: Marc E. Agronin, MD Guest: Richard S. Isaacson, MD TBD

Host: Marc E. Agronin, MD Guest: Richard S. Isaacson, MD TBD

CME credits: 1.00 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-biomarkers-in-alzheimers-disease/14651/ TBD

Host: Marc E. Agronin, MD Guest: Richard S. Isaacson, MD TBD

CME credits: 1.00 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/additional-treatments-for-alzheimers-disease/14656/ TBD

CME credits: 1.00 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/prevention-of-alzheimers-disease/14657/ TBD

CME credits: 1.00 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/clinical-trials-in-alzheimers-disease/14658/ TBD

CME credits: 0.50 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/transforming-cervical-cancer-screening-and-management-new-guidelines-new-tests-a-case-based-discussion/14676/ Experts discuss the ACS and ASCCP CCV screening guidelines and review the benefits of primary screening and the latest data driven testing options. Is Pap cytology a thing of the past? Find out more about harmonization of guidelines from leading experts, Drs. Cantrell, Stoler and Huh. You might just transform your clinical practice.

CME credits: 0.25 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/tentative-approval-understanding-the-fda-ruling-on-once-nightly-sodium-oxybate/14688/ While most clinicians are aware of a drug being either “approved” or “not approved” by the FDA, many are not familiar with the term “tentative approval.” Leading experts, attorney Sara Koblitz, JD, and Dr. Michael Thorpy, review the FDA approval process, explore how “tentative approval” is currently impacting treatment in the field of sleep medicine, and discuss how “non-drug” issues are related to delayed FDA approval. Review the latest safety and efficacy pivotal trial data associated with once-nightly sodium oxybate and find out if we're truly on the cusp of a new awakening in sleep medicine.

CME credits: 0.25 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/talking-rare-epidemiology-and-pathogenesis-of-apol1-mediated-kidney-disease/14781/ End-stage kidney disease (ESKD) is at least 3x higher among African Americans compared to Americans of European descent. Carriers of APOL1 variants with chronic kidney disease (CKD) are associated with more rapid disease progression and an increased risk of kidney failure. Join Drs. Martin Pollak and Susanne Nicholas as they discuss the epidemiology and possible mechanisms of APOL1 kidney disease, as well as recent clinical evidence for therapies in development that can potentially prevent rapid disease progression.

CME credits: 1.00 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/how-to-make-an-early-diagnosis/14650/ TBD

Host: Ethan Craig, MD, MHS Guest: Dr. Lianne Gensler, MD To help us understand how axial spondyloarthritis (axSpA) and inflammatory back pain (IBP) differ, Dr. Ethan Craig is joined by Dr. Lianne Gensler from the UCSF Spondylitis Clinic at the University of California San Francisco Medical Center. Dr. Craig and Dr. Gensler are Novartis consultants. 249165 11/22

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Masja de Haas, MD, PhD Program Chairman:Roberto Romero, MD, DMedSciChief, Perinatology Research BranchDivision of Maternal-Fetal Medicine and ObstetricsDivision of Intramural ResearchNICHD/NIH/DHHSEditor-in-Chief for ObstetricsThe American Journal of Obstetrics and Gynecology Neonatal alloimmune neutropenia (NAIN or NIN) is a neutrophil blood group antagonism similar to HDFN and FNAIT. Its presentation varies clinically and ranges from asymptomatic to severe manifestations such as sepsis and meningitis. Listen in as Drs. Masja de Haas and Lee Shulman discuss clinical clues that should catch your eye. Discover novel yet simple ways to be vigilant and make the right clinical calls.

CME credits: 0.25 Valid until: 29-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/alloimmune-neutropenia-of-the-fetus-and-newborn/13910/ Program Chairman:Roberto Romero, MD, DMedSciChief, Perinatology Research BranchDivision of Maternal-Fetal Medicine and ObstetricsDivision of Intramural ResearchNICHD/NIH/DHHSEditor-in-Chief for ObstetricsThe American Journal of Obstetrics and Gynecology Neonatal alloimmune neutropenia (NAIN or NIN) is a neutrophil blood group antagonism similar to HDFN and FNAIT. Its presentation varies clinically and ranges from asymptomatic to severe manifestations such as sepsis and meningitis. Listen in as Drs. Masja de Haas and Lee Shulman discuss clinical clues that should catch your eye. Discover novel yet simple ways to be vigilant and make the right clinical calls.

CME credits: 0.25 Valid until: 29-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-bone-health-in-postmenopausal-post-fracture-patients/14662/ Life-altering secondary fractures are a harsh reality, but Medicare studies show, and orthopedic surgeons agree, that knowledge has not translated into prevention. Why is there clinical inertia in providing preventative interventions related to secondary fragility fractures? Join Drs. Andrea Singer and Susan Bukata as they provide a cogent medical approach to preventing these fractures and a roadmap for when and how to use available therapies based on their mechanisms of action.

CME credits: 0.25 Valid until: 27-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-to-common-questions-about-met-exon-14skipping-mutations-in-nsclc/14678/ Non-small cell lung cancer (NSCLC) is a highly heterogeneous disease, and research has evolved its diagnosis and treatment through the discovery of genetic alterations and molecular pathways, personalizing treatment based on tumor mutation(s). The molecular characterization of tumors using techniques such as next-generation sequencing (NGS) has expanded the understanding of actionable molecular alterations, and in tandem has accelerated the development of drugs to inhibit alterations with greater specificity, leading to the development of novel target-selected agents in NSCLC. The NCCN Guidelines strongly advise assessment of at least 8 targets for NSCLC by NGS, including MET exon 14–skipping mutations (METex14). The FDA has approved two MET inhibitors, capmatinib and tepotinib, for patients with METex14 metastatic NSCLC, and there is ongoing research for other targeted agents. Studies have established that treatment with MET-targeted therapies improves outcomes in patients with METex14, as opposed to patients receiving chemotherapy and/or immunotherapy, which generate a modest activity response. AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer to verify where clinical practice gaps exist. That's why this activity will …

CME credits: 0.50 Valid until: 05-01-2024 Claim your CME credit at https://reachmd.com/programs/cme/current-and-emerging-roles-of-immunotherapy-and-adcs-for-patients-with-non-muscle-invasive-and-muscle-invasive-bladder-cancer/14553/ Do you know how to best utilize immunotherapy and antibody-drug conjugates to improve treatment outcomes in your patients with metastatic urothelial cancer? Listen in as Drs. Mamta Parikh and Daniel Petrylak break down the data surrounding these therapies so you can improve the care you provide.

CME credits: 0.50 Valid until: 05-01-2024 Claim your CME credit at https://reachmd.com/programs/cme/current-standards-and-future-opportunities-for-adcs-in-advancedmetastatic-triple-negative-breast-cancer/14551/ Antibody-drug conjugates have transformed the treatment of triple-negative breast cancer (TNBC). Tune in to hear about approved ADCs and others in development and find out where they fit into the NCCN Guidelines for TNBC.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Eugenia Shmidt, MD The pregnancy inflammatory bowel disease and neonatal outcomes (PIANO) registry is the largest US-based study that examines pregnant women who have inflammatory bowel disease (IBD). So how can clinicians use the takeaways from this study in their practice? Join Dr. Peter Buch as he discusses IBD in pregnant women with Dr. Eugenia Shmidt, Assistant Professor in the Division of Gastroenterology, Hepatology, and Nutrition at the University of Minnesota.

CME credits: 0.50 Valid until: 05-01-2024 Claim your CME credit at https://reachmd.com/programs/cme/selecting-and-sequencing-immunotherapies-for-patients-with-advanced-rcc/14554/ Do you know how to best utilize immunotherapy to improve treatment outcomes in your patients with metastatic renal cell cancer? Listen as Drs. Eric Jonasch and Bradley McGregor discuss the data and guidelines surrounding selecting and sequencing immunotherapy for your patients.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: John Mascarenhas, MD There are several challenges and limitations associated with the current therapeutic options available for myelofibrosis-related anemia, leading to a recent push to transform the treatment paradigm. Joining Dr. Charles Turck to share strategies for optimizing the care of patients with myelofibrosis-related anemia is Dr. John Mascarenhas, Director of the Center of Excellence for Blood Cancers and Myeloid Disorders at the Mount Sinai Tisch Cancer Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Srdan (Serge) Verstovsek, MD, PhD What's the role of the JAK-STAT pathway in myelofibrosis, and what are the key genetic mutations and biomarkers we need to be aware of? Explore the pathophysiology of myelofibrosis with Dr. Charles Turck and Dr. Serge Verstovsek, Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Miguel Regueiro, MD The horizon for patients with Crohn's disease is looking promising as new treatments are expected to come out in the next few years. So what are the best practices for treating fistulizing Crohn's disease? Explore the treatment landscape with Dr. Peter Buch and Dr. Miguel Regueiro, Chair of the Digestive Disease and Surgery Institute at Cleveland Clinic.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Zobair M Younossi MD, MPH, FACP, FACG, AGAF, FAASLD Guest: Scott D. Isaacs, MD FACP, FACE Recently, the American Association of Clinical Endocrinology and the American Association for the Study of Liver Diseases released guideline updates on nonalcoholic steatohepatitis (NASH). How will these updates impact clinical practice? Drs. Zobair M.Younossi and Scott D. Isaacs join Dr. Charles Turck to share their insights on these updated guidelines.

Host: Aaron Gerds, MD There are two key unmet needs in the treatment of myelofibrosis. Here to share what those are and how we can work to address them is Dr. Aaron Gerds from the Cleveland Clinic.

Host: Ross M. Maltz, MD Guest: Shail M. Govani, MD, MSc Guest: Nana E. Bernasko, CRNP, WHNP-BC, DNP Guest: Shubha Bhat, PharmD, MS, BCACP As new therapies evolve, including biosimilars, it's important for clinicians, patients, and caregivers to understand the similarities, differences, and potential risks and benefits of these therapies. Join our panel of experts to find out more about key concepts and best practices to educate your patients.

Host: Ross M. Maltz, MD Guest: Shail M. Govani, MD, MSc Guest: Nana E. Bernasko, CRNP, WHNP-BC, DNP Guest: Shubha Bhat, PharmD, MS, BCACP As new therapies evolve, including biosimilars, it's important for clinicians, patients, and caregivers to understand the similarities, differences, and potential risks and benefits of these therapies. Join our panel of experts to find out more about key concepts and best practices to educate your patients.

CME credits: 0.50 Valid until: 21-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/utilization-and-management-of-antibody-drug-conjugates-in-metastatic-breast-cancer-the-relationship-between-adcs-and-her2/14552/ New data for sequencing antibody-drug conjugates (ADCs) in HER2 metastatic breast cancer have hit the conference circuit. Listen as Drs. William Gradishar, Javier Cortés, and Hope Rugo dissect the data surrounding ADCs in different types of HER2 metastatic breast cancer. Make sure you're up to date and offering your patients the best care.

CME credits: 0.50 Valid until: 20-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/treating-iron-deficiency-in-patients-with-hfref-a-review-of-the-recent-data-for-iv-iron-replacement-therapy/13508/ Symptoms from iron deficiency can greatly affect the overall quality of life of our patients with heart failure. Recent clinical evidence from the IRONMAN trial explores the use of IV iron replacement in patients with chronic heart failure. Join Drs. Javed Butler, Stefan Anker, Piotr Ponikowski, and Robert Mentz as they discuss the clinical trial design and outcomes from IRONMAN compared to the current body of evidence for managing iron deficiency in this setting.

HPV testing plays an important role in cervical cancer screening, but not every patient whose HPV-positive will develop cervical cancer. One option that can help us identify which HPV-positive patients are truly at risk is CINtec PLUS Cytology, an immunohistochemistry test that simultaneously detects p16 and Ki67 biomarker proteins. Learn more about how this dual staining technique works in this video.

Host: John Buse, MD, PhD Guest: Jennifer B. Green, MD What does the latest research on glycemia reduction show us about the impact of glucose-lowering medication in combination with metformin on microvascular and cardiovascular outcomes in patients with type 2 diabetes? Dr. John Buse speaks with one of the study's investigators, Dr. Jennifer Green, a Professor of Medicine at Duke University, about this emerging data.

CME credits: 0.25 Valid until: 20-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/improving-outcomes-in-patients-with-ovarian-cancer-multidisciplinary-patient-centered-care/14565/ Follow along as Dr. Floortje Backes walks us through a patient case and demonstrates the shared decision-making process of selecting an appropriate maintenance treatment regimen for advanced ovarian cancer.

Host: Charles P. Vega, MD Guest: Kareen Y. Espino, MD What is cultural humility, and how can it be incorporated into clinical practice? How does a patient's culture impact their health behaviors, and why does your own culture and your “practice” approach matter? Listen in as 2 leading experts navigate concerns surrounding cultural humility and emphasize the importance of empathy while they review tips for improved communication with Latino patients. There are easy ways to integrate small but meaningful changes into your clinical practice to help bridge communication gaps and enable your patients to live healthier lives.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Nancy S. Reau, MD The most common liver disease caused by pregnancy is intrahepatic cholestasis of pregnancy (ICP). So what do clinicians need to know to best treat their patients? Explore the impact of liver disease on pregnancy as Dr. Peter Buch is joined by Dr. Nancy S. Reau, Professor in the Department of Internal Medicine at Rush Medical College.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Bryson Katona, MD, PhD Lynch syndrome is the most common cause of inherited colon cancer and is often underdiagnosed. How can we improve detection of these patients? To find out more, Dr. Peter Buch joins Dr. Bryson Katona from the Hospital of the University of Pennsylvania to explore some key detection strategies.